Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures
Authors:
Open Access
- 1 October 1994
- journal article
- Published by American Society of Hematology in Blood
- Vol. 84 (7) , 2269-2277
Abstract
Long-term bone marrow cultures (LTBMC) from patients with multiple myeloma (MM) and normal donors were analyzed for immunophenotype and cytokine production. Both LTBMC adherent cells from myeloma and normal donor origin expressed CD10, CD13, the adhesion molecules CD44, CD54, vascular cell adhesion molecule 1, very late antigen 2 (VLA-2), and VLA- 5, and were positive for extracellular matrix components fibronectin, laminin, and collagen types 3 and 4. LTBMC from myeloma patients and normal donors spontaneously secreted interleukin-6 (IL-6). However, levels of IL-6 correlated with the stage of disease; highest levels of IL-6 were found in LTBMC from patients with active myeloma. To identify the origin of IL-6 production, LTBMC from MM patients and normal donors were cocultured with BM-derived myeloma cells and cells from myeloma cell lines. IL-6 was induced by plasma cell lines that adhered to LTBMC such as ARH-77 and RPMI-8226, but not by nonadhering cell lines U266 and FRAVEL. Myeloma cells strongly stimulated IL-6 secretion in cocultures with LTBMC adherent cells from normal donors and myeloma patients. When direct cellular contact between LTBMC and plasma cells was prevented by tissue-culture inserts, no IL-6 production was induced. This implies that intimate cell-cell contact is a prerequisite for IL-6 induction. Binding of purified myeloma cells to LTBMC adherent cells was partly inhibited by monoclonal antibodies against adhesion molecules VLA-4, CD44, and lymphocyte function-associated antigen 1 (LFA-1) present on the plasma cell. Antibodies against VLA-4, CD29, and LFA-1 also inhibited the induced IL-6 secretion in plasma cell-LTBMC cocultures. In situ hybridization studies performed before and after coculture with plasma cells indicated that LTBMC adherent cells produce the IL-6. These results suggest that the high levels of IL-6 found in LTBMC of MM patients with active disease are a reflection of their previous contact with tumor cells in vivo. These results provide a new perspective on tumor growth in MM and emphasize the importance of plasma cell-LTBMC interaction in the pathophysiology of MM.Keywords
This publication has 11 references indexed in Scilit:
- Cytokine gene expression in human multiple myelomaBritish Journal of Haematology, 1993
- CD44 and Its Interaction with Extracellular Matrix1993
- Detection of calcitonin and calcitonin gene‐related peptide mRNA in human medullary thyroid carcinoma. A retrospective studyThe Journal of Pathology, 1993
- VLA-4-fibronectin interaction is required for the terminal differentiation of human bone marrow cells capable of spontaneous and high rate immunoglobulin secretion.Journal of Experimental Medicine, 1992
- Integrins: Versatility, modulation, and signaling in cell adhesionCell, 1992
- Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the diseaseBlood, 1991
- Interleukin 6 (IL‐6) and its receptor: Their role in plasma cell neoplasiasStem Cells, 1991
- A family of cell-surface glycoproteins defined by a putative anti-endothelial cell receptor antibody in man.The Journal of Immunology, 1989
- Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas.Proceedings of the National Academy of Sciences, 1986
- The Synergism of Aecessory Cells and of Soluble a‐Factors Derived from Them in the Activation of B Cells to ProliferationImmunological Reviews, 1984